Insuman Implantable (Insulin Human)

• Insuman Implantable, a human insulin, acts on the endocrine pathway to lower elevated blood glucose in diabetes.
• Type 1 diabetes mellitus: provides basal insulin to achieve glycemic control.
• Type 2 diabetes mellitus: supplements endogenous insulin to improve glucose regulation.
• Gestational diabetes mellitus: may be used when oral agents are insufficient to maintain target glucose levels.

• Insulin Human binds to the insulin receptor on cell membranes, activating the intrinsic tyrosine kinase activity. This triggers a cascade involving IRS proteins, PI3‑K and AKT, leading to translocation of GLUT‑4 transporters to the plasma membrane and increased glucose uptake in muscle and adipose tissue. Concurrently, hepatic gluconeogenesis is suppressed, and glycogen synthesis is promoted, thereby lowering circulating glucose.

Insuman Implantable may be associated with a range of adverse reactions, varying from frequent to rare.

Common Side Effects

• Hypoglycemia: low blood sugar episodes, especially if dose exceeds needs.
• Weight gain: increased caloric storage due to improved glucose utilization.
• Injection site pain or irritation: discomfort at the implantation site.
• Lipodystrophy: localized changes in fat tissue at the site of administration.

Serious or Rare Side Effects

• Allergic reactions including anaphylaxis: may present with rash, swelling, or respiratory distress.
• Hypokalemia: low potassium levels, potentially leading to cardiac arrhythmias.
• Edema: fluid retention causing swelling of extremities.
• Insulin antibody formation: may alter insulin effectiveness and cause hypersensitivity.

• Before initiating therapy with Insuman Implantable, several precautionary measures should be considered.
• Dose adjustment: tailor dose based on blood glucose monitoring and renal function.
• Renal impairment: reduce dose and monitor closely for hypoglycemia.
• Hepatic dysfunction: use with caution as metabolism may be altered.
• Pregnancy and lactation: evaluate risk‑benefit and consult a specialist.
• Concomitant hypoglycemic agents: increase monitoring to avoid severe hypoglycemia.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insuman Implantable can interact with other medicines, influencing its glucose‑lowering effect.

Major Interactions (Avoid)

• Sulfonylureas or meglitinides: risk of severe hypoglycemia.
• Beta‑adrenergic blockers: may mask hypoglycemia symptoms.
• Glucocorticoids: may antagonize insulin effect, requiring dose increase.

Moderate Interactions (Monitor Closely)

• ACE inhibitors and ARBs: may enhance insulin sensitivity, monitor glucose levels.
• Thiazide diuretics: can raise blood glucose, adjust insulin dose as needed.
• Oral contraceptives: may affect insulin requirements, necessitating closer monitoring.